Intellia Therapeutics Prices Public Offering of Common Stock

Trending News 🌥️

Intellia Therapeutics Intrinsic Stock Value – Intellia Therapeutics ($NASDAQ:NTLA) is a biotech company that uses CRISPR-based gene editing technology to develop therapies for a range of diseases. The company has priced an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million. Intellia intends to use the funds to advance its clinical programs, including its ongoing Phase 1 trial in transthyretin amyloidosis, as well as for research and development and general corporate purposes.

Price History

Intellia Therapeutics Inc., a leading gene editing company, announced Thursday that it has priced its public offering of common stock at $45.8 per share. This is a 11.0% plunge from the previous closing price of $51.5. The offering is expected to raise gross proceeds of approximately $300 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

The company plans to use the net proceeds from the offering for research and development activities, including clinical trials, working capital and general corporate purposes. Intellia Therapeutics’ proprietary technology platform enables the company to target a broad range of diseases, including genetic diseases, infectious diseases, and cancer. Live Quote…

About the Company

VI Analysis – Intellia Therapeutics Intrinsic Stock Value

Intellia Therapeutics is a company that is focused on developing gene editing treatments. The company’s fundamentals reflect its long term potential. The intrinsic value of Intellia Therapeutics’ shares is around $75.8, which is calculated by the VI Line. Currently, the company’s stock is traded at $45.8, which means it is undervalued by 40%. More…

VI Peers

The company was founded in 2014 and is based in Cambridge, Massachusetts. Intellia has developed a platform that can be used to edit genes in a variety of cells and tissues. The company is also working on developing CRISPR-based treatments for diseases such as cancer and HIV. Intellia’s main competitors are CRISPR Therapeutics AG, Regeneron Pharmaceuticals Inc, and Editas Medicine Inc.

– CRISPR Therapeutics AG ($NASDAQ:CRSP)

Crispr Therapeutics AG is a biopharmaceutical company that focuses on the development of CRISPR/Cas9-based therapeutics for serious diseases. The company’s market cap as of 2022 is 4.28B and its ROE is -18.27%. Crispr Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland.

– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)

Regeneron Pharmaceuticals Inc is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s products include EYLEA, Praluent, Dupixent, Libtayo, and Kevzara. As of 2021, the company had a market cap of $80.72 billion and a return on equity of 19.7%. Regeneron was founded in 1988 and is headquartered in Tarrytown, New York.

– Editas Medicine Inc ($NASDAQ:EDIT)

Editas Medicine Inc is a genome editing company based in Cambridge, Massachusetts. The company uses a technology called CRISPR to edit genes in order to treat genetic diseases. As of 2022, Editas Medicine Inc has a market cap of 886.02M and a Return on Equity of -23.75%. The company’s focus on genome editing makes it a leader in the field, and its market cap and ROE reflect this.

Summary

Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on developing CRISPR-based gene editing therapies to treat serious diseases. Investors may be interested in Intellia Therapeutics as a way to bet on the future of CRISPR-based gene editing therapies. The company is still in the early stages of development, but has already shown promise in animal studies. If Intellia can continue to advance its pipeline of therapies, it could become a leader in this emerging field.